DK0804070T3 - Fremgangsmåde til isolering af proteiner fra mælk - Google Patents

Fremgangsmåde til isolering af proteiner fra mælk

Info

Publication number
DK0804070T3
DK0804070T3 DK94910120T DK94910120T DK0804070T3 DK 0804070 T3 DK0804070 T3 DK 0804070T3 DK 94910120 T DK94910120 T DK 94910120T DK 94910120 T DK94910120 T DK 94910120T DK 0804070 T3 DK0804070 T3 DK 0804070T3
Authority
DK
Denmark
Prior art keywords
milk
interest
isolating proteins
solubility
component
Prior art date
Application number
DK94910120T
Other languages
Danish (da)
English (en)
Inventor
Julie S Denman
Edward S Cole
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK0804070T3 publication Critical patent/DK0804070T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C3/00—Preservation of milk or milk preparations
    • A23C3/08—Preservation of milk or milk preparations by addition of preservatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/832—Milk; colostrum

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Dairy Products (AREA)
  • Tea And Coffee (AREA)
DK94910120T 1993-03-09 1994-02-17 Fremgangsmåde til isolering af proteiner fra mælk DK0804070T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2839593A 1993-03-09 1993-03-09
PCT/US1994/001672 WO1994019935A1 (en) 1993-03-09 1994-02-17 Isolation of components of interest from milk

Publications (1)

Publication Number Publication Date
DK0804070T3 true DK0804070T3 (da) 2000-08-07

Family

ID=21843236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94910120T DK0804070T3 (da) 1993-03-09 1994-02-17 Fremgangsmåde til isolering af proteiner fra mælk

Country Status (11)

Country Link
US (1) US5756687A (es)
EP (1) EP0804070B1 (es)
JP (1) JP3801196B2 (es)
AT (1) ATE193301T1 (es)
AU (1) AU693436B2 (es)
DE (1) DE69424687T2 (es)
DK (1) DK0804070T3 (es)
ES (1) ES2146648T3 (es)
GR (1) GR3033500T3 (es)
PT (1) PT804070E (es)
WO (1) WO1994019935A1 (es)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
EP0933029A1 (en) * 1998-02-03 1999-08-04 Xyrofin Oy Skimmed milk powder substitute
EP0947464A1 (en) * 1998-04-01 1999-10-06 Single Buoy Moorings Inc. Fluid transfer boom with coaxial fluid ducts
US20030005468A1 (en) * 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
WO2000030436A1 (en) * 1998-11-19 2000-06-02 Ppl Therapeutics (Scotland) Ltd. Stabilisation of milk from transgenic animals
US7030289B2 (en) 1998-11-19 2006-04-18 Ppl Therapeutics (Scotland) Ltd Stabilization of milk from transgenic animals
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
CA2368608A1 (en) * 1999-05-13 2000-11-23 Genzyme Transgenics Corp. Transgenically produced antithrombin iii and mutants thereof
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20040226052A1 (en) * 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
DZ3494A1 (fr) * 2001-01-05 2002-07-11 Pfizer Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
WO2002077161A2 (en) * 2001-03-12 2002-10-03 Progenetics Llc Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses
AU2002307554A1 (en) * 2001-04-23 2002-11-05 Abgenix, Inc. Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
EP1463522A4 (en) * 2001-05-16 2005-04-13 Einstein Coll Med HUMAN ANTI-PNEUMOCOCCAL ANTIBODIES FROM NON-HUMAN ANIMALS
US20030036637A1 (en) * 2001-06-13 2003-02-20 Scott Fulton Purification of human serum albumin
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
JP2005529873A (ja) * 2002-04-12 2005-10-06 メダレックス インコーポレイテッド Ｃｔｌａ−４抗体を使用した治療の方法
KR100473703B1 (ko) * 2002-08-23 2005-03-10 한미약품 주식회사 형질전환 동물의 젖으로부터 재조합 펩타이드 또는단백질의 정제 방법
TWI268933B (en) * 2003-06-10 2006-12-21 Animal Technology Inst Taiwan Method for separating protein from animal milk
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
JP4315982B2 (ja) 2004-01-09 2009-08-19 ファイザー インコーポレイティッド ＭＡｄＣＡＭに対する抗体
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
WO2005112968A2 (en) * 2004-04-30 2005-12-01 Gtc Biotherapeutics, Inc. Method of using recombinant human antithrombin for neurocognitive disorders
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
JP5112863B2 (ja) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス ヒト抗−ｋｉｒ抗体
MX2007000610A (es) 2004-07-16 2007-03-07 Pfizer Prod Inc Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
AU2005291486A1 (en) * 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US20090238820A1 (en) 2005-03-08 2009-09-24 Allan Corey M ANTI-MAdCAM ANTIBODY COMPOSITIONS
ES2716874T3 (es) 2005-03-23 2019-06-17 Genmab As Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
EP1868647A4 (en) 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
DOP2006000093A (es) 2005-04-25 2007-01-31 Pfizer Anticuerpos contra miostatina
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
PT2447283E (pt) 2005-09-07 2015-10-08 Pfizer Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
JP2009518446A (ja) 2005-12-07 2009-05-07 メダレックス インコーポレーティッド Ｃｔｌａ−４抗体投与量漸増レジメン
US9181344B2 (en) 2005-12-15 2015-11-10 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
WO2007118214A2 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
WO2008019036A2 (en) * 2006-08-04 2008-02-14 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
CN101522717A (zh) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
TW200821026A (en) * 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
DK2081595T3 (da) 2006-09-26 2019-07-15 Genmab As Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
US8020576B2 (en) * 2006-10-26 2011-09-20 Delaware Capital Formation, Inc. Emergency shutoff valve for use in a fuel dispensing system
US8394927B2 (en) 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
ES2556214T3 (es) 2007-11-12 2016-01-14 U3 Pharma Gmbh Anticuerpos para AXL
JP5677703B2 (ja) 2008-01-10 2015-02-25 リサーチ ディベロップメント ファウンデーション Ｅｈｒｌｉｃｈｉａｃｈａｆｆｅｅｎｓｉｓにのためのワクチンおよび診断
WO2009148575A1 (en) 2008-05-30 2009-12-10 Xbiotech, Inc. Interleukin-1 alpha abs and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2270053A1 (en) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
US8785600B2 (en) 2009-10-23 2014-07-22 Millennium Pharmaceuticals, Inc. Anti-GCC antibody molecules and related compositions and methods
WO2011084145A2 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
EP2384766A1 (en) 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2640744A4 (en) 2010-11-19 2014-05-28 Eisai R&D Man Co Ltd NEUTRALIZATION OF ANTIBODIES TO CCL20
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
CN105601741A (zh) 2011-04-15 2016-05-25 卡姆普根有限公司 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
CN103945862A (zh) * 2011-07-07 2014-07-23 Lfb美国股份有限公司 使蛋白质稳定的制剂
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
DK2581387T3 (en) 2011-10-11 2015-12-07 Université D Aix Marseille An anti-HIV-1 Tat monoclonal antibody
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
JP6251730B2 (ja) 2012-04-26 2017-12-20 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
EP3492101A3 (en) 2012-05-10 2019-10-23 Massachusetts Institute Of Technology Agents for influenza neutralization
SA113340642B1 (ar) 2012-06-15 2015-09-15 فايزر إنك أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها
WO2014025546A2 (en) 2012-08-07 2014-02-13 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2956480B1 (en) 2013-02-13 2019-09-04 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
WO2014144666A2 (en) 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN105358228A (zh) 2013-07-05 2016-02-24 法国血液分割暨生化制品实验室 亲和层析基质
US9993566B2 (en) 2013-08-28 2018-06-12 Abbvie Stemcentrx Llc SEZ6 modulators and methods of use
CN106103483A (zh) 2014-01-13 2016-11-09 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
MX2016009991A (es) 2014-02-11 2016-10-07 Massachusetts Inst Technology Nuevo anticuerpo anti-dengue de espectro completo.
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
WO2016007414A1 (en) 2014-07-08 2016-01-14 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
BR112017003582B1 (pt) 2014-08-27 2024-01-09 Memorial Sloan Kettering Cancer Center Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico
CA2961323C (en) 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions
KR20180026659A (ko) 2015-03-18 2018-03-13 더 존스 홉킨스 유니버시티 포타슘 채널 kcnk9를 표적화하는 신규한 모노클로날 항체 억제제
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10358503B2 (en) 2015-08-13 2019-07-23 New York University Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
CA3007301A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
GEP20217222B (en) 2016-07-12 2021-02-10 Lundbeck A/S H Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3491136A1 (en) 2016-07-28 2019-06-05 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Anti- immunoglobulin g aptamers and uses thereof
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
WO2018109213A1 (en) 2016-12-16 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Aptamers directed against a kappa light chain-containing protein and uses thereof
MA47019A (fr) 2016-12-16 2021-04-21 H Lundbeck As Agents, utilisations et procédés
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7062669B2 (ja) 2016-12-23 2022-05-06 ブリストル－マイヤーズ スクイブ カンパニー 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
MA47205A (fr) 2017-01-04 2019-11-13 H Lundbeck As Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
CN111032694B (zh) 2017-07-14 2024-03-08 辉瑞大药厂 针对madcam的抗体
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
KR20210044183A (ko) 2018-05-07 2021-04-22 젠맵 에이/에스 항-pd-1 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
BR112020022265A2 (pt) 2018-05-07 2021-02-23 Genmab A/S método para tratar câncer em um indivíduo, e, estojo.
UA127902C2 (uk) 2018-10-30 2024-02-07 Генмаб А/С Застосування комбінації антитіла проти vegf і кон'югата антитіло проти тканинного фактора-лікарський засіб для лікування раку
WO2021091815A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
MX2022005222A (es) 2019-11-07 2022-06-08 Genmab As Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
KR20220109435A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 B형 간염 감염 치료에서의 사용을 위한 인터페론-결합된 항원 결합 단백질
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
AU2021262744A1 (en) 2020-04-27 2022-10-06 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
EP3909601A1 (en) 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
TW202216210A (zh) 2020-06-29 2022-05-01 丹麥商珍美寶股份有限公司 抗組織因子抗體－藥物共軛體類和彼等於治療癌症之用途
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
EP4175982A1 (en) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
WO2022108931A2 (en) 2020-11-17 2022-05-27 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
JP2024521958A (ja) 2021-06-09 2024-06-04 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング コロナウイルス感染の処置又は予防のための使用のためのインターフェロン会合抗原結合性タンパク質
IL312110A (en) 2021-10-29 2024-06-01 Seagen Inc Cancer treatment methods with a combination of anti-PD-1 antibody and antibody-CD30 conjugate
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
TW202408583A (zh) 2022-05-06 2024-03-01 丹麥商珍美寶股份有限公司 使用抗組織因子抗體－藥物共軛體以治療癌症之方法
WO2024036265A2 (en) 2022-08-12 2024-02-15 Takeda Vaccines, Inc. Novel anti-denv3 antibodies
WO2024097725A1 (en) 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5165945A (en) * 1987-07-23 1992-11-24 Schreiber Foods, Inc. Cheese and process and system for making it
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
JPH04365487A (ja) * 1990-04-11 1992-12-17 Consortium Elektrochem Ind Gmbh 組換ｄｎａ−構造体、組換ベクター、トランスゲン動物の乳からの蛋白質の取得法、トランスゲン動物の製法及びトランスゲン動物の乳
US5175013A (en) * 1990-12-31 1992-12-29 The Pillsbury Company Frozen dessert compositions and products
FR2677652B1 (fr) * 1991-06-12 2005-05-27 Agronomique Inst Nat Rech Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee.
US5178894A (en) * 1991-09-26 1993-01-12 Silvia P. Rudel High non-fat milk content bread products having improved keeping qualities

Also Published As

Publication number Publication date
WO1994019935A1 (en) 1994-09-15
EP0804070A1 (en) 1997-11-05
AU6268394A (en) 1994-09-26
EP0804070B1 (en) 2000-05-24
ES2146648T3 (es) 2000-08-16
DE69424687D1 (de) 2000-06-29
DE69424687T2 (de) 2000-09-07
AU693436B2 (en) 1998-07-02
JPH08510721A (ja) 1996-11-12
GR3033500T3 (en) 2000-09-29
PT804070E (pt) 2000-11-30
ATE193301T1 (de) 2000-06-15
US5756687A (en) 1998-05-26
JP3801196B2 (ja) 2006-07-26

Similar Documents

Publication Publication Date Title
DK0804070T3 (da) Fremgangsmåde til isolering af proteiner fra mælk
DE122009000068I2 (de) Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
ATE144777T1 (de) Brett-stabiles produkt und verfahren zur isolierung der rna, dna und proteine
NO20001052L (no) 1C, 15N, 2H merkede proteiner for NMR-strukturbestemmelser og deres fremstilling
GR3032843T3 (en) Methods and compositions for detecting binding of ligand pair using non-fluorescent label
DE69207228D1 (de) Isolierverfahren von Proteinen durch Ultrafiltration
FI883708A (fi) Menetelmä emäksisten proteiinien eristämiseksi proteiiniseoksista, jotka sisältävät tällaisia emäksisiä proteiineja
DK0408029T3 (da) Fremgangsmåde til fraktionering af plasmaprotein
DK162233C (da) Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
ATE258598T1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
DK1123367T3 (da) Fremgangsmåde til separation af lipider og proteiner fra biologisk materiale
DE3865963D1 (de) Elektrophoretisches gel hoher aufloesung sowie methode zur abscheidung von serumproteinen.
DE3865998D1 (de) Verfahren und system zur gewinnung und ausscheidung von effekten gleichzeitig auftretender quellen eines elektromagnetischen feldes und ihre anwendung bei der vorhersage von erdbeben.
DK0894091T3 (da) Fremgangsmåde til oprensning af et protein fra en proteinholdig opløsning
DK1054897T3 (da) Fremgangsmåde til oprensning af PrPres ud fra en biologisk pröve og anvendelser deraf
DK260186D0 (da) Fremgangsmaade til fjernelse af det n-terminale metionin fra metionylproteiner
DK1036166T3 (da) Fremgangsmåde til ekstraktion af udklækningsvæske fra atlantisk laks og anvendelse af denne væske
FI921059A (fi) Menetelmä hyötyproteiinien erittämiseksi hiivoista
DK159441C (da) 11-substituerede 5,11-dihydro-6h-dibenz(b,e)azepin-6-on-derivater, laegemidler indeholdende disse forbindelser og analogifremgangsmaade til forbindelsernes fremstilling
GR3025929T3 (en) Ein isolation and purification of lung surfactant prot
ATE117994T1 (de) Verfahren zur herstellung von 2-chlor-5- chlormethylpyridin.
CA2157118A1 (en) Isolation of components of interest from milk
DK0401657T3 (da) Fremgangsmåde til C-terminal modificering af proteiner
DK0415557T3 (da) Separation af antimetalchelat-antistoffer
DK146591D0 (da) Fremgangsmaade og mellemprodukt til fremstilling af azetidinsulfonsyrederivater